The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11151 malaria professionals are enjoying the free benefits of MalariaWorld today

MSP2

NOT Open Access | Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2

February 25, 2021 - 08:17 -- NOT Open Access
Author(s): 
Das SC, Price JD, Norton RS, et al.
Reference: 
Vaccine. 2021 Feb 20:S0264-410X(21)00158-4

Merozoite surface protein 2 (MSP2) is a highly abundant, GPI-anchored surface antigen on merozoites of the malaria parasite Plasmodium falciparum. It consists of highly conserved N- and C-terminal domains, and a central polymorphic region that allows all MSP2 alleles to be categorized into the 3D7 or FC27 family. Previously it has been shown that epitope accessibility differs between lipid-bound and lipid-free MSP2, suggesting that lipid interactions modulate the conformation and antigenicity in a way that may better mimic native MSP2 on the merozoite surface.

Genetic polymorphisms of Plasmodium falciparum isolates from Melka-Werer, North East Ethiopia based on the merozoite surface protein-2 (msp-2) gene as a molecular marker

February 15, 2021 - 15:45 -- Open Access
Author(s): 
Hussein Mohammed, Ashenafi Assefa, Melkie Chernet, Yonas Wuletaw and Robert J. Commons
Reference: 
Malaria Journal 2021 20:85, 12 February 2021

The characterization of parasite populations circulating in malaria endemic areas is necessary to evaluate the success of ongoing interventions and malaria control strategies. This study was designed to investigate the genetic diversity of Plasmodium falciparum isolates from the semi-arid area in North East Ethiopia, using the highly polymorphic merozoite surface protein-2 (msp2) gene as a molecular marker.

Merozoite Surface Protein 2 Adsorbed onto Acetalated Dextran Microparticles for Malaria Vaccination

December 15, 2020 - 14:22 -- Open Access
Author(s): 
Stiepel RT, Batty CJ, MacRaild CA, Norton RS, Bachelder E, Ainslie KM
Reference: 
Int J Pharm. 2020 Dec 9:120168

Malaria remains a global health threat, with significant morbidity and mortality worldwide despite current interventions. The human disease is caused by five different parasitic species, with Plasmodium falciparum being the deadliest. As a result, vaccine research against P. falciparum is a global priority. Merozoite surface protein 2 (MSP2) is a promising vaccine antigen as MSP2-specific antibodies have been shown previously to be protective against malaria infection.

Subscribe to RSS - MSP2